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AbstrAct
We have earlier reported the reduction of total 
cholesterol, low-density lipoprotein (LDL) cholesterol 
and oxidized LDL caused by short-term modification 
of diet with cold-pressed turnip rapeseed oil (CPTRO) 
instead of butter. The aim of this supplementary 
study was to determine whether the beneficial 
effects resulted from altered cholesterol metabolism 
during the intervention. 
Thirty-seven men with metabolic syndrome 
(MetS) completed an open, randomized and 
balanced crossover study. Subjects’ usual diet was 
supplemented with either 37.5 g of butter or 35 mL 
of CPTRO for 6–8 weeks. Otherwise normal dietary 
habits and physical activity were maintained without 
major variations. Serum non-cholesterol sterols 
were assayed with gas–liquid chromatography 
and used as surrogate markers of whole-body 
cholesterol synthesis and absorption efficiency. 
Serum proprotein convertase subtilisin/kexin type 9 
(PCSK9) concentration was analyzed with Quantikine 
ELISA Immunoassay. Serum cholesterol synthesis 
markers and serum cholestanol (absorption marker), 
all as ratios to cholesterol, did not differ between 
the periods. Serum campesterol and sitosterol ratios 
to cholesterol were significantly increased after 
the administration of CPTRO resulting from the 
increased intake of 217 mg/day of plant sterols in 
CPTRO. Serum PCSK9 concentration did not differ 
between CPTRO and butter periods. 
The reduction in serum cholesterol by 7.2% after 
consumption of rapeseed oil could not be explained 
by changes in cholesterol absorption, synthesis or 
PCSK9 metabolism in MetS.
triAl registrAtion number
 ClinicalTrials. gov NCT01119690.
introduction
Metabolic syndrome (MetS) is a combina-
tion of cardiovascular risk factors such as 
visceral obesity, hypertension, dyslipidemia and 
abnormal glucose tolerance or diabetes. Cardio-
vascular disease and all-cause mortality are 
increased in men with MetS.1 A comprehensive 
meta-analysis of 951 083 patients demonstrated 
that MetS is associated with a twofold increase 
in adverse cardiovascular outcomes and a 
1.5–fold increase in all-cause mortality.2 The 
increase in overweight and obesity is a global 
phenomenon and contributes to an increase in 
subjects with MetS as well. The accumulation of 
cholesterol in the arterial walls is known to play 
a key role in the development and progression 
of atherosclerosis.
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significance of this study
What is already known about this subject?
 ► Rapeseed oil consumption decreases 
serum total and low-density lipoprotein 
cholesterol concentration when compared 
with butter.
 ► Serum non-cholesterol sterols are generally 
considered valid biomarkers of cholesterol 
absorption efficiency and cholesterol 
synthesis.
 ► Recent evidence has demonstrated that 
linoleic acid (n–6 polyunsaturated fatty 
acid), also present in turnip rapeseed 
oil, decreased serum proprotein 
convertase subtilisin/kexin type 9 (PCSK9) 
concentration.
What are the new findings?
 ► Cholesterol absorption efficiency 
markers campesterol and sitosterol were 
significantly higher after a period of 
6–8 weeks of cold-pressed turnip rapeseed 
oil (CPTRO) when compared with butter.
 ► However, CPTRO contains high amounts of 
campesterol and sitosterol and there was 
no difference in the endogenous cholesterol 
absorption marker cholestanol.
 ► CPTRO had no effect in the markers 
of cholesterol synthesis or PCSK9 
concentrations when compared with butter.
How might these results change the focus 
of research or clinical practice?
 ► A diet low in saturated fatty acids and rich 
in unsaturated fatty acids such as in CPTRO 
has beneficial effects on serum lipids. 
Further studies are necessary to determine 
the mechanisms since the reduction could 
not be explained by changes in whole-body 
cholesterol or PCSK9 metabolism.
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Figure 1 The study design. CPTRO, cold-pressed turnip rapeseed oil; MetS, metabolic syndrome.
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An easily reproducible way to impact populations’ cardio-
vascular risk is implementation of a heart healthy diet. The 
so-called traditional Mediterranean diet low in saturated 
fatty acids (SFA) and rich in unsaturated fatty acids derived 
from olive oil, nuts, fruits, vegetables and fish has been 
shown to decrease the incidence and mortality of cardiovas-
cular diseases.3–5 Olive oil’s counterparts in the North-Eu-
ropean and Canadian diet are rapeseed oil (canola oil) and 
turnip rapeseed oil, which also contain large amounts of 
unsaturated fatty acids, and are the most typical sources of 
dietary plant-derived n–three polyunsaturated fatty acids 
(PUFA).
Unsaturated fatty acid consumption has several favorable 
effects on serum and lipoprotein lipids. We have earlier 
reported the beneficial effects of dietary intake of cold-
pressed turnip rapeseed oil (CPTRO) on low-density lipo-
protein (LDL) cholesterol and oxidized LDL concentrations 
compared with butter in men with MetS.6 We found that 
LDL cholesterol concentration was reduced by 11% and 
that of oxidized LDL by 15% compared with butter with 
no effect on high-density lipoprotein (HDL) cholesterol 
and serum triglyceride concentrations. CPTRO, as rapeseed 
oils in general, contains on average over 95% of unsatu-
rated fatty acids, of which two-thirds are monounsaturated 
fatty acids (MUFA) and one-third PUFA.6 Regarding the 
cholesterol-lowering mechanism of rapeseed oil compared 
with an SFA-based control diet, two of three earlier 
studies7–9 demonstrated that after substitution of rapeseed 
oil-based diet serum biomarkers of cholesterol absorption 
diminished7 and those of cholesterol synthesis increased.7 8 
In the third study, however, cholesterol synthesis did not 
differ from that of the baseline diet in spite of a signifi-
cant reduction of total and LDL cholesterol.9 In a fourth 
study comparing rapeseed oil and olive oil consumption 
in subjects with ileostomy, serum cholesterol levels were 
lower, fecal cholesterol excretion was higher and choles-
terol absorption tended to be lower during rapeseed oil 
than olive oil diet.10 Thus, three of the four earlier rape-
seed oil diet studies suggested that rapeseed oil interfered 
with cholesterol metabolism. All of these previous studies 
were performed in non-obese mildly to moderately hyper-
cholesterolemic subjects. Since cholesterol metabolism 
differs in subjects with MetS from those without MetS,11 12 
it is possible that rapeseed oil consumption might have 
a different impact on cholesterol metabolism in MetS 
compared with non-obese hypercholesterolemic subjects 
without MetS. Recent evidence has also demonstrated 
that linoleic acid (n–6 PUFA), also present in CPTRO, 
decreased serum proprotein convertase subtilisin/kexin 
type 9 (PCSK9) concentration suggesting that this may be 
a possible cholesterol-lowering mechanism of linoleic acid 
consumption.13 PCSK9 is a protease that regulates choles-
terol metabolism by binding to hepatic LDL receptors and 
promoting their degradation. This is a continuation and 
further elaboration to our earlier study. The aim of this 
supplementary study was to evaluate whether the reduction 
in cholesterol concentration by CPTRO in men with MetS 
results from alterations in cholesterol metabolism assayed 
with serum non-cholesterol sterols, biomarkers of whole-
body cholesterol synthesis and absorption efficiency,14–16 
and/or from alterations in serum PCSK9 concentrations 
and to do so by performing further analysis of samples 
collected in our original trial.
mAteriAls And metHods
subjects, design and diets
Hämeenlinna Metabolic Syndrome research program is a 
regional study investigating atherosclerotic risk factors in 
men with MetS.17 We have earlier described the detailed 
structure, methods, baseline data and the results of this 
dietary intervention on LDL cholesterol, oxidized LDL and 
arterial elasticity.6 In brief, 37 men with MetS according to 
the National Cholesterol Education Program Adult Treat-
ment Panel III criteria18 and age from 35 to 65 years (mean 
53.5) accomplished the clinical phase of a randomized and 
balanced study with two open dietary interventions in a 
crossover design.
The subjects were randomly divided into turnip rapeseed 
oil and butter groups. In the oil period, in addition to their 
habitual diet the subjects consumed a daily dose of 35 mL 
CPTRO, and during the butter period they consumed 37.5 g 
of butter. Both dietary periods lasted from 6 to 8 weeks. 
After the first period, all subjects had an 8-week wash-out 
period before changing to the group of the other fat adjunct 
for another period of 6–8 weeks (figure 1). The subjects 
were asked to maintain their diet and amount of physical 
activity otherwise unchanged throughout the study. CPTRO 
contained 96% of MUFA and PUFA. Butter contained 62% 
of SFA. The composition of cholesterol, plant sterols, 
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table 1 Cholesterol and non-cholesterol sterol composition in 
butter and in cold-pressed turnip rapeseed oil
Variables butter mg/100 g butter cPtro mg/100 g oil
Cholesterol 188.8 3.1
Campesterol 0.5 255.0
Sitosterol 0.2 333.7
Stigmasterol 0.1 1.1
Avenasterol 0.3 25.1
Sitostanol 0.5 4.7
Squalene 6.1 1.2
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sitostanol and squalene in butter and CPTRO is shown in 
table 1.
The Ethics Committee of the Kanta-Häme Hospital 
District approved the study protocol and the study followed 
the ethical principles outlined in the Declaration of Helsinki. 
Each study subject gave a written informed consent for the 
study.
blood sampling and biochemical analysis
Blood samples were collected into 10 mL EDTA tubes, 5 mL 
lithium-heparin gel tubes and 2 mL natrium-fluoride tubes 
at the end of both dietary periods after a 12-hour overnight 
fast and at least 10 min of rest.
Serum PCSK9 concentration was analyzed with the Quan-
tikine ELISA Immunoassay using a monoclonal catcher and 
a polyclonal detection antibody specific for human PCSK9 
(www. rndsystems. com/ pdf/ DPC900. pdf). According to the 
manufacturer, the intra-assay and interassay %CVs (coeffi-
cient of variability) vary from 4.1% to 6.5%, and the mean 
serum concentration in 37 apparently healthy subjects was 
313 (SD 71.5) ng/mL and the range was 177–460 ng/mL.
Cholesterol and non-cholesterol sterols in serum, butter 
and CPTRO were quantified by gas–liquid chromatography 
(GLC) with a 50 m Ultra 2 capillary column (Agilent 6890N 
Network GC System, Agilent Technologies) as described 
previously.19 Serum non-cholesterol sterols were expressed 
as the ratio of 100 × μmol/mmol of cholesterol by adjusting 
the concentrations with the cholesterol value in the same 
GLC run. Ratios of serum cholesterol precursors to choles-
terol (squalene, cholestenol, desmosterol and lathosterol) 
reflect whole-body cholesterol synthesis,15 16 whereas the 
ratios of plant sterols (campesterol, sitosterol and avenas-
terol) and cholestanol reflect cholesterol absorption effi-
ciency.14–16 We also calculated the lathosterol–cholestanol 
ratio, which reflects cholesterol metabolism.15
statistical analysis
We made a sample size calculation for the secondary 
end points now studied. For the effect of 7% (SD of the 
change=0.14; alpha=0.05, two tailed), we needed 31–32 
patients to yield power of 80%. Statistical analysis was 
carried out with IBM SPSS Statistics V. 23 software. The 
Kolmogorov-Smirnov and Shapiro-Wilk tests were used to 
test the data for Gaussian distribution. Results are presented 
as mean±SEM for normally distributed data and as median 
and IQR for not normally distributed results. Compar-
ison of outcome measurements after diets was performed 
using paired samples t-test or Wilcoxon signed-rank test 
for dependent samples, according to the normality of data 
distribution. p Values<0.05 were considered significant.
results
After both periods, cholesterol precursors (squalene, 
cholestenol, desmosterol and lathosterol as ratios to 
cholesterol) were interrelated (r-values from 0.517 to 
0.943, p<0.001 for all). Likewise, the absorption markers 
cholestanol, campesterol, sitosterol and avenasterol were 
interrelated after both interventions (r-values from 0.498 
to 0.778, p<0.002). The markers of synthesis absorption 
correlated inversely with each other after both interven-
tions suggesting that cholesterol homeostasis was intact 
(eg, lathosterol–cholestanol ratio to cholesterol, CPTRO: 
r=−0.498, p=0.002, and butter: r=−0.692, p=0.000).
In addition to the different composition of fatty acids in 
butter and CPTRO, the amount of cholesterol and non-cho-
lesterol sterols were different (table 1). Thus, regarding the 
advised daily intake of 35 mL CPTRO and 37.5 mg butter, 
the intake of cholesterol was 1 mg in CPTRO versus 71 mg 
in butter, and those of plant sterols 217 mg in CPTRO 
versus 0.6 mg in butter. Serum cholesterol concentration 
was 0.38±0.01 mmol/L (7.2%) lower after the CPTRO 
period compared with the butter period (p<0.001)(table 2).
The ratios of cholesterol synthesis markers to choles-
terol did not differ between the CPTRO and butter periods 
(table 2). Of the absorption markers, cholestanol and aven-
asterol ratios to cholesterol were similar after both periods. 
However, the ratios of campesterol and sitosterol to choles-
terol were 39% and 16% higher after the CPTRO period 
compared with those of butter (p<0.001 for both). The 
only interference of statin treatment was that in subjects on 
statin, the difference in sitosterol ratios to cholesterol was 
non-significant between the intervention groups. The latho-
sterol/cholestanol ratios were similar after both periods. 
The concentrations of oxidized LDL did not correlate with 
serum non-cholesterol sterols after either treatment. Serum 
PCSK9 concentrations did not differ between CPTRO and 
butter periods (table 2).
discussion
The main new findings in this supplementary study of our 
earlier randomized cross-over intervention were that in 
spite of significant serum cholesterol reduction by 7.2% 
assayed with GLC dietary period of 6–8 weeks of supple-
mentary CPTRO did not affect cholesterol absorption 
efficiency, cholesterol synthesis, or serum PCSK9 concen-
tration when compared with the dietary period of butter 
in men with MetS. Because of the higher daily plant sterol 
intake in CPTRO compared with butter (217 mg vs 1 mg), 
serum plant sterol ratios to cholesterol increased on average 
by 21% after the CPTRO versus butter diets. The result is 
comparable to earlier rapeseed oil interventions, in which 
the consumption of rapeseed oil containing 360–388 mg/
day of plant sterols increased their serum concentrations by 
33%–37%.7 10
The evaluation of absolute whole-body cholesterol 
metabolism is laborious both for the study participants 
and the laboratory. Thus, since the serum non-choles-
terol sterols have turned out to reliably reflect choles-
terol metabolism,14–16 20–24 they are generally considered 
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table 2 Serum PCSK9 and cholesterol concentrations and non-cholesterol sterol ratios to cholesterol after consumption of butter and 
CPTRO
Variables butter n=37 cPtro n=37 p Value
PCSK9, ng/mL 214.2 (191.2 to 237.2) 229.3 (197.1 to 229.3) 0.248
Cholesterol, mmol/L 5.30 (4.87 to 5.73) 4.92 (4.50 to 5.33) <0.001
Markers of cholesterol synthesis
  Squalene* 14.9 (10.5 to 19.2) 13.7 (10.4 to 17.1) 0.792
  Cholestenol* 17.0 (12.1 to 22.0) 16.5 (9.8 to 23.2) 0.850
  Desmosterol* 95.2 (79.7 to 110.7) 89.0 (78.2 to 99.8) 0.792
  Lathosterol* 122.6 (85.3 to 159.8) 111.0 (72.8 to 149.3) 0.645
Markers of cholesterol absorption efficiency
  Cholestanol* 138.3 (128.0 to 148.6) 138.1 (126.4 to 149.7) 0.541
  Campesterol* 199.7 (150.3 to 249.1) 277.0 (224.0 to 330.0) <0.001
  Sitosterol* 97.7 (86.3 to 109.2) 113.1 (104.0 to 122.2) <0.001
  Avenasterol* 33.0 (27.7 to 38.2) 35.0 (28.9 to 41.0) 0.734
Marker of cholesterol metabolism
  Lathosterol/cholestanol, µg/ µg 0.76 (0.36 to 1.16) 0.80 (0.61 to 1.00) 0.934
Values shown are median and 95% CI of the median except mean and 95% CI of the mean for total cholesterol.
*100 x μmol/mmol of cholesterol.
CPTRO, cold-pressed turnip rapeseed oil; PCSK9, proprotein conversin subtilisin/kexin 9.
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valid biomarkers of cholesterol absorption efficiency and 
cholesterol synthesis. In this study, cholesterol homeostasis 
was intact after both dietary periods (cholesterol absorp-
tion efficiency and cholesterol synthesis were interrelated) 
suggesting that the non-cholesterol sterols reflected choles-
terol metabolism as expected in this intervention. However, 
we applied serum cholestanol to cholesterol ratio to eval-
uate cholesterol absorption efficiency instead of serum 
plant sterols because of the unbalanced amount of plant 
sterols in the diets. Under these conditions, it is likely that 
serum plant sterol levels primarily reflect their increased 
intake and not cholesterol absorption efficiency. Choles-
tanol is an endogenous metabolite of cholesterol and its 
serum concentration is practically diet unrelated so that it 
serves as a reliable biomarker of cholesterol absorption also 
under these conditions.
Rapeseed oil consumption decreases serum total and 
LDL cholesterol concentration,6–9 25 HDL cholesterol 
concentration either remains unchanged,6 8 25 increases,7 or 
decreases,9 and serum triglycerides remain unchanged6 8 9 
or decrease7 25 when compared with diets rich in SFA. The 
cholesterol-lowering mechanisms of rapeseed oil have been 
studied by evaluating cholesterol metabolism and LDL 
apoprotein B turnover studies. Thus, rapeseed oil consump-
tion compared with high SFA or olive oil-based diets 
decreased cholesterol absorption efficiency,7 10 increased 
compensatorily cholesterol synthesis7 8 and increased fecal 
cholesterol excretion10 in three out of four studies.7–10 The 
inhibition of cholesterol absorption is probably based on 
the high plant sterol content in rapeseed oil. In the study 
by Ellegård et al,10 the diets between rapeseed and olive 
oil were otherwise completely comparable including the 
cholesterol, fiber and energy contents and the fatty acid 
profiles except that the mean plant sterol concentration was 
584 mg/day in the rapeseed oil diet versus 258 mg/day in 
the olive oil diet. This difference, about 300 mg/day of plant 
sterols, is large enough to alter cholesterol metabolism. In 
a well-controlled dietary intervention, Lin et al26 compared 
serum lipids, non-cholesterol sterols and variables of 
cholesterol metabolism during consumption of diets with 
naturally occurring plant sterols 126 or 449 mg/2000 kcal/
day. Serum total, LDL and HDL cholesterol and serum 
triglycerides were similar between the two diets, but choles-
terol absorption efficiency and serum cholestanol to choles-
terol ratio were significantly lower during the 449 mg/2000 
kcal diet than the 126/2000 kcal diet, and total cholesterol 
excreted into feces and serum lathosterol to cholesterol 
ratio were significantly higher. Thus, the higher plant sterol 
intake interfered with cholesterol absorption efficiency and 
increased cholesterol synthesis and neutral sterol excretion.
Regarding lipoprotein turnover studies, it is known that 
diets rich in unsaturated fatty acids, mainly PUFAs, increase 
LDL receptor activity27 increasing the uptake of choles-
terol into tissues, and decrease very low density lipopro-
tein (VLDL) and LDL production rates28 29 followed by 
diminished circulating cholesterol concentration. It can 
be assumed that the increased cholesterol synthesis during 
rapeseed oil diet also upregulates the LDL receptor activity 
because of their mutual cellular regulatory mechanisms.
Why was cholesterol metabolism unchanged in spite 
of LDL cholesterol lowering after CPTRO in this study? 
The similar serum PCSK9 concentrations during both diets 
confirmed that PCSK9 metabolism was not affected by 
CPTRO although serum PCSK9 concentration was lower 
than during a linoleic acid-enriched diet than during the 
SFA diet.13 One possible reason for the unresponsiveness 
of cholesterol metabolism could be the metabolic profile of 
cholesterol in the study population. Subjects with MetS in 
general have low absorption efficiency and high synthesis 
of cholesterol (low absorption/high synthesis).11 12 It is 
conceivable that the type of the metabolic profile may have 
an impact on the individual’s response to changes in choles-
terol absorption or cholesterol synthesis. There is evidence 
that subjects who have low absorption/high synthesis of 
cholesterol responded less effectively to cholesterol absorp-
tion inhibition with plant stanols than subjects with high 
absorption/low synthesis.30 In fact, in addition to a smaller 
cholesterol reduction the changes in serum campesterol 
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and sitosterol were also more modest in subjects with low 
absorption/high synthesis than in those with high absorp-
tion/low synthesis, a finding which also could explain our 
negative results. In another study, subjects with high choles-
terol synthesis mimicking the metabolic profile in MetS 
were non-responders to cholesterol absorption inhibition 
during plant sterol consumption.31 There are also controver-
sial results, for example, in a third study no indication was 
found that individuals could be classified as either preferen-
tial statin responders or ezetimibe responders based on their 
baseline profile of cholesterol metabolism.32 However, the 
reduced intake of cholesterol and SFA in CPTRO compared 
with butter is able to lower LDL cholesterol concentration 
by upregulating LDL receptor activity and downregulating 
VLDL and LDL production.27–29
One of the potential limitations of this trial is that the 
study population included only men with MetS, and thus 
the findings cannot be generalized to represent the whole 
population. Second, due to the nature of the dietary inter-
vention only the research personnel performing the labora-
tory measurements were blinded about the diet periods but 
not the subjects. Third, this study was an examination of 
secondary end points from samples collected in an earlier 
trial with different primary endpoint.
In conclusion, modifying the diet with CPTRO instead 
of butter in men with MetS significantly lowered LDL 
cholesterol concentration, but the reduction could not be 
explained by changes in whole-body cholesterol or PCSK9 
metabolism.
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